Limited transscleral cyclophotocoagulation for silicone oil-induced glaucoma in eyes with good visual potential

Table 1 Details of the 12 patients undergoing limited transscleral cyclophotocoagulation

Pt. no	Age, sex	One-eyed status	Lens status, silicone oil status	IOP pre in mmHg	IOP LFU in mmHg	Vision pre as logMAR	Vision LFU as logMAR	AGM pre	AGM LFU	Repeat surgery for IOP	Visual success	IOP success
1	19, M	Yes	Aphakic, SOR	30	10	1.2	1.3	2	5	Yes	Yes	No
2	14, F	Yes	Aphakic, SO in situ	48	17	1.2	1.2	1	2	Yes	Yes	No
3	10, M	No	Aphakic, SO in situ	18	32	1.0	2.2	4	3	No	No	No
4	31, M	No	Aphakic, SO in situ	48	17	1.3	1.8	5	1	Yes	No	No
5	15, M	No	Phakic, SOR	16	16	1.2	1.2	3	2	No	Yes	Yes
6	53, M	Yes	Pseudophakic, SOR	40	14	0.6	0.7	4	1	No	Yes	Yes
7	20, M	Yes	Aphakic, SOR	29	4	1.1	0.9	5	2	Yes	Yes	No
8	38, M	No	Pseudophakic, SOR	17	50	1.3	1.5	4	5	No	No	No
9	37, M	No	Pseudophakic, SO in situ	15	17	0.6	0.7	5	0	No	Yes	Yes
10	33, M	Yes	Aphakic, SOR	32	25	1.0	0.7	5	2	Yes	Yes	Yes
11	34, M	No	Aphakic, SOR	26	19	0.6	0.6	4	2	No	Yes	Yes
12	29, F	No	Aphakic, SOR	58	26	1.3	1.1	6	5	Yes	Yes	No

AGM: Anti-glaucoma medication; F: Female; IOP: Intraocular pressure; LFU: Last follow up; LogMAR: Logarithm of the minimum angle of resolution; M: Male; Pt. no: Patient number; SO: Silicone oil; SOR: Silicon oil removal.

Table 2 Demographic and clinical details, n (%)

Parameter	Value
Median age at TSCPC in years	28.3 (15-34)
Sex as male: Female	10:2
One-eyed patients	5 (41.7)
Eyes with prior SOR	9 (75)
Non-glaucoma intraocular surgeries	2 (1-2)
Duration between VR surgery and high IOP in months	4.8 (3.8-11.1)
Pre-operative glaucoma surgery	2 (16.7) both AGV
Lens status as Phakic: Pseudophakic: Aphakic	1:3:8
Interval between SOI and TSCPC in months, n = 12	9 (5-19)
Interval between SOI and TSCPC in months, n = 3 without SOR	18 (5-97)
Interval between SOI and TSCPC in months, n = 9 with SOR	7 (5-12)
Duration between VR surgery and SOR in months, n = 9	3 (2.1-3.9)
Interval between SOR and TSCPC in months, n = 9	3.4 (2.3-5.5)
Pre-operative vision as logMAR	1.06 (0.6-1.2)
Pre-operative IOP in mmHg	29.5 (17-40)
Pre-operative CDR	0.8 (0.5-0.9)
Pre-operative AGM	4 (3-5)
Follow-up duration in months	21.5 (14.2-31.6)

Data are presented as n (%) or median (interquartile range). AGM: Anti-glaucoma medication; AGV: Ahmed glaucoma valve; CDR: Cup-to-disc ratio; IOP: Intraocular pressure; IQR: Interquartile range; LogMAR: Logarithm of the minimum angle of resolution; SOI: Silicone oil injection; SOR: Silicone oil removal; TSCPC: Transscleral cyclophotocoagulation; VR: Vitreoretinal.

Table 3 Trend of change of visual acuity, intraocular pressure and anti-glaucoma medication after transscleral cyclophotocoagulation, mean ± SE

Timepoint	Vision as logMAR	IOP in mmHg	Number of AGMs
Pre-operative	1.03 ± 0.10	31.4 ± 3.0	4.0 ± 0.4
Day 1	1.15 ± 0.10	18.4 ± 3.1	2.6 ± 0.4
Week 1	0.93 ± 0.12	18.7 ± 3.8	2.6 ± 0.5
Week 5	0.95 ± 0.10	20.3 ± 3.1	2.4 ± 0.4
Month 3	1.14 ± 0.11	21.2 ± 3.6	2.8 ± 0.5
Month 6	1.02 ± 0.11	23.8 ± 3.2	3.1 ± 0.5
Year 1	1.21 ± 0.11	18.8 ± 3.4	2.2 ± 0.5
Year 2	1.16 ± 0.11	23.5 ± 3.4	2.9 ± 0.5

AGM: Anti-glaucoma medication; IOP: Intraocular pressure; LogMAR: Logarithm of minimum angle of resolution.